Sanuwave Health (NASDAQ:SNWV) Posts Quarterly Earnings Results

Sanuwave Health (NASDAQ:SNWV) posted its quarterly earnings results on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $9.74 million for the quarter. Sanuwave Health had a negative return on equity of 450.56% and a net margin of 35.96%.

Sanuwave Health Stock Up 0.5%

Sanuwave Health stock traded up $0.03 during mid-day trading on Thursday, reaching $6.00. 67,380 shares of the company were exchanged, compared to its average volume of 127,618. The company has a debt-to-equity ratio of 8.15, a quick ratio of 0.99 and a current ratio of 1.31. The firm has a market cap of $51.60 million, a P/E ratio of 18.18 and a beta of 1.48. The business has a fifty day moving average of $10.12 and a 200 day moving average of $17.23. Sanuwave Health has a 12-month low of $5.77 and a 12-month high of $46.58.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Legal & General Group Plc bought a new stake in Sanuwave Health during the second quarter valued at about $26,000. BNP Paribas Financial Markets bought a new position in Sanuwave Health in the second quarter worth about $46,000. Russell Investments Group Ltd. purchased a new stake in shares of Sanuwave Health during the third quarter valued at about $67,000. State of Alaska Department of Revenue purchased a new stake in shares of Sanuwave Health during the fourth quarter valued at about $96,000. Finally, New York State Common Retirement Fund bought a new stake in shares of Sanuwave Health in the 2nd quarter valued at about $102,000. 42.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Sanuwave Health in a research note on Wednesday, June 24th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $51.00.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.